About: The expression level of angiotensin-converting enzyme 2 determines the severity of COVID-19: lung and heart tissue as targets

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The expression level of angiotensin-converting enzyme 2 determines the severity of COVID-19: lung and heart tissue as targets Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	The expression level of angiotensin-converting enzyme 2 determines the severity of COVID-19: lung and heart tissue as targets
Creator	Falahati, Mojtaba Sharifi, Majid Babadaei, Nejadi Bloukh, Haj Edis, Zehra Hasan, Anwarul Kachooei, Ehsan Mahdi, Mohammad
source	Medline; PMC
abstract	Researchers have reported some useful information about the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) leading to CoV disease 2019 (COVID-19). Several studies have been performed in order to develop antiviral drugs, from which a few have been prescribed to patients. Also, several diagnostic tests have been designed to accelerate the process of identifying and treating COVID-19. It has been well-documented that the surface of host cells is covered by some receptors, known as angiotensin-converting enzyme 2 (ACE2), which mediates the binding and entry of CoV. After entering, the viral RNA interrupts the cell proliferation system to activate self-proliferation. However, having all the information about the outbreakof the SARS-COV-2, it is not still clear which factors determine the severity of lung and heart function impairment induced by COVID-19. A major step in exploring SARS-COV-2 pathogenesis is to determine the distribution of ACE2 in different tissues . In this review, the structure and origin of CoV, the role of ACE2 as a receptor of SARS-COV-2 on the surface of host cells, and the ACE2 distribution in different tissues with a focus on lung and cardiovascular system have been discussed. It was also revealed that acute and chronic cardiovascular diseases (CVDs) may result in the clinical severity of COVID-19. In conclusion, this review may provide useful information in developing some promising strategies to end up with a worldwide COVID-19 pandemic. Communicated by Ramaswamy H. Sarma
has issue date	2020-06-01(xsd:dateTime)
bibo:doi	10.1080/07391102.2020.1767211
bibo:pmid	32397951
has license	no-cc
sha1sum (hex)	d2ea7bf5c23e485cf37efc32b39935a88b9cb97b
schema:url	https://doi.org/10.1080/07391102.2020.1767211
resource representing a document's title	The expression level of angiotensin-converting enzyme 2 determines the severity of COVID-19: lung and heart tissue as targets
has PubMed Central identifier	PMC7284141
has PubMed identifier	32397951
schema:publication	J Biomol Struct Dyn
resource representing a document's body	covid:d2ea7bf5c23e485cf37efc32b39935a88b9cb97b#body_text
is schema:about of	named entity 'CARDIOVASCULAR DISEASES' named entity 'REVIEW' named entity 'IS COVERED' named entity 'diagnostic tests' named entity 'cardiovascular' named entity 'pathogenesis' named entity 'lung' named entity 'receptor' named entity 'cell proliferation' named entity 'gastrointestinal disorders' named entity 'ACE2' named entity 'SARS-CoV-2' named entity 'COVID' named entity 't-distributed Stochastic Neighbor Embedding' named entity 'SARS-CoV-2' named entity 'chromosome' named entity 'pneumonia' named entity 'human lung' named entity 'mucosa' named entity 'CVD' named entity 'lungs' named entity 'cigarette smokers' named entity 'epithelial cells' named entity 'acute myocarditis' named entity 'MERS-CoV' named entity 'widley' named entity 'SARS CoV' named entity 'viruses' named entity 'renin-angiotensin' named entity 'left ventricular hypertrophy' named entity 'SARS' named entity 'COVID' named entity 'receptor binding domain' named entity 'CVDs' named entity 'COVID' named entity 'COVID' named entity 'cardiovascular' named entity 'influenza' named entity 'alveolar' named entity 'respiratory symptoms' named entity 'ICU' named entity 'SARS-CoV-2' named entity 'COVID-19.' named entity 'ACE2' named entity 'ACE2' named entity 'diabetics' named entity 'ACE2' named entity 'ACE2' named entity 'COVID' named entity 'diabetics' named entity 'SARS-CoV' named entity 'infection' named entity 'SARS-CoV-2' named entity 'assay' named entity 'COVID' named entity 'elderly people' named entity 'respiratory failure' named entity 'animal origin' named entity 'Marban' named entity 'respiratory illness' named entity 'kidney' named entity 'vertebrates' named entity 'ACE2' named entity 'CVDs' named entity 'pneumonia' named entity 'fatality rate' named entity 'ACE2' named entity 'MERS' named entity 'Peeri' named entity 'ACE2' named entity 'SARS-CoV-2' named entity 'angiotensin 2' named entity 'vascular endothelial function' named entity 'multiple organ failure'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software